|
Active substance |
elexacaftor / tezacaftor / ivacaftor |
|
Holder |
Vertex Pharmaceuticals Incorporated. |
|
Status |
Closed |
|
Indication |
Cystic fibrosis (CF) patients in critical need who are 12 years of age and older, heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes) |
|
Public documents |
|
| Approbation amendment 2 | |
|
Last update |
09/08/2022 |
VX-445/TEZ/IVA
Last updated on 13/09/2024